Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)
Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%
Castle Biosciences pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Castle Biosciences's pe ratio was 32.3× on Apr 30, 2025, against 100.4× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 32.3× | −100.9 |
| 2024 | Dec 31, 2024 | 133.3× | −288.8 |
| 2020 | Oct 30, 2020 | 422.1× | +339.3 |
| 2019 | Dec 31, 2019 | 82.8× | – |
See a number that looks wrong?